Clinical relevance of chromosomal aberrations in bone and soft tissue tumors in children and young adults
Authors:
E. Stejskalová 1; M. Jarošová 2; J. Mališ 1; D. Sumerauer 1; H. Urbánková 2; L. Krsková 3; K. Pýcha 4; J. Schovanec 5; J. Balcárková 2; V. Šmelhaus 1; D. Kodetová 3; J. Starý 1
Authors place of work:
Klinika dětské hematologie a onkologie 2. LF UK a FN Motol, Praha2 Hemato-onkologická klinika FN a LF UP Olomouc3 Ústav patologické anatomie a molekulární medicíny 2. LF UK a FN Motol, Praha4 Klinika dětské chirurgie 2. LF UK a FN Motol, Praha5 Ortopedick
1
Published in the journal:
Klin Onkol 2009; 22(2): 58-66
Category:
Původní práce
Summary
Backgrounds:
We present the results of a cytogenetic and molecular cytogenetic analysis of a series of patients with bone and soft tissue tumors.
Patients and methods:
We analyzed a cohort of 26 patients with Ewing sarcoma/PNET, 15 patients with rhabdomyosarcoma, 5 with synovial sarcoma and one patient with an undifferentiated sarcoma using the cytogenetic and molecular cytogenetic techniques M-FISH and arrayCGH.
Results:
We found nonrandom chromosomal structural and numerical changes with diagnostic and prognostic relevance in most patients. Eight patients with ES/PNET had only a t(11;22)(q24;q12), eight patients had secondary aberrations as well and six had only secondary aberrations. In the RMS patients we detected the t(1;13)(p36;q14) once and the t(2;13)(q35;q14) four times, both of them characteristic for the alveolar subtype with poor prognosis and numerical aberrations, characteristic for the embryonal subtype, in five patients. Four patients with synovial sarcoma had the diagnostic t(X;18)(p11.2;q11.2), one of them had a complex karyotype with a complex t(X;18;21) (p11.2;q11.2;q11.2) together with t(2;5)(q24–32;p13–14) and t(12;20)(p11;q13). We correlated the karyotype of cancer cells with histopathologic morphologic analysis, clinical outcome and foreign published results.
Conclusion:
Cytogenetic and molecular cytogenetic analysis is a valuable diagnostic tool in bone and soft tissue tumors, especially in less differentiated subtypes, and as such it should be an integral part of curative care.
Key words:
Ewing sarcoma/PNET – rhabdomyosarcoma – synovial sarcoma – children – adolescent – cytogenetics – arrayCGH – M-FISH – chromosomes
Zdroje
1. Koutecký J a kol. Nádorová onemocnění dětí a mladistvých. Praha: Karolinum 1997.
2. Lazar A, Abruzzo LV, Pollock RE et al. Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas. Arch Pathol Lab Med 2006; 130: 1199–11207.
3. Sandberg AA. Cytogenetics and molecular genetics of bone and soft-tissue tumors. Am J Med Genet 2002; 115: 189–193.
4. Slater O, Shipley J. Clinical relevance of molecular genetics to paediatric sarcomas. J Clin Pathol 2007; 60: 1187–1194.
5. Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology 2006; 48: 13–21.
6. Miettinen M. From morphological to molecular diagnosis of soft tissue tumors. Adv Exp Med Biol 2006; 587: 99–113.
7. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors-Ewing sarcoma and peripheral primitive neuroectodermal tumors. Cancer Genet Cytogenet 2000; 123(1): 1–26.
8. Zhao L, Hayes K, Van Fleet T et al. Detection of a novel reciprocal t(16;22)(q11.2;q12) in a Ewing sarcoma. Cancer Genet Cytogenet 2003; 140: 55–57.
9. de Alava E. Molecular pathology in sarcomas. Clin Transl Oncol 2007; 9: 130–144.
10. Zielenska M, Zhang MZ, Kwan N et al. Acquisition of secondary structural chromosomal changes in pediatric Ewing sarcoma is a probable prognostic factor for tumor response and clinical outcome. Cancer 2001; 91: 2156–2164.
11. Hattinger CM, Rumpler S, Strehl S et al. Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Genes Chromosom Cancer 1999; 24: 243–254.
12. Hattinger CM, Potschger U, Tarkkanen M et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer 2002; 86: 1763–1769.
13. McManus AP, Min T, Swansbury GJ et al. Der(16) t(1;16)(q21;q13) as a secondary change in alveolar rhabdomyosarcoma. A case report and review of the literature. Cancer Genet Cytogenet 1996; 87: 179–181.
14. Day SJ, Nelson M, Rosenthal H et al. Der(16)t(1;16) (q21;q13) as a secondary structural aberration in yet a third sarcoma, extraskeletal myxoid chondrosarcoma. Genes Chromosomes Cancer 1997; 20: 425–427.
15. Kullendorff CM, Mertens F, Donner M et al. Cytogenetic aberrations in Ewing sarcoma: are secondary changes associated with clinical outcome? Med Ped Oncol 1999; 32: 79–83.
16. Steenman M, Westerveld A, Mannens M. Genetics of Beckwith-Wiedemann syndrome associated tumors: common genetic pathways. Genes Chromosomes Cancer 2000; 28: 1–13.
17. ACT cytogenetics laboratory manual. In: Barch MJ (ed). ACT cytogenetics laboratory manual. 2nd ed. New York: Raven Press 1991.
18. Stejskalová E, Jarošová M, Kabíčková E et al. Primary mediastinal (thymic) large B-cell lymphoma with a der(14)t(8;14)(q24;q32) and a translocation of MYC to the derivative chromosome 14 with a deleted IgH locus. Cancer Genet Cytogenet 2006; 170: 158–162.
19. Shaffer LG, Tommerup N (eds). ISCN 2005: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger 2005.
20. Rosoff PM, Hatcher S, West DC. Biphenotypic sarcoma with characteristics of both a Ewing sarcoma and a desmoplastic small round cell tumor. Med Pediatr Oncol 2000; 34: 407–412.
21. Sorensen PHB, Shimada H, Liu XF et al. Biphenotypic sarcomas with myogenic and neural differentiation express the Ewing’s sarcoma EWS/FLI1 fusion gene. Cancer Res 1995; 55: 1385–1392.
22. Thorner P, Squire J, Chilton-MacNeil S et al. Is the EWS/FLI-1 fusion transcript specific for Ewing sarcoma and peripheral primitive neuroectodermal tumor? A report of four cases showing this transcript in a wider range of tumor types. Am J Pathol 1996; 148: 1125–1138.
23. Richkind KE, Romansky SG and Finklestein JZ. t(4;19)(q35;q13.1): A recurrent change in primitive mesenchymal tumors? Cancer Genet Cytogenet 1996; 87: 71–74.
24. Somers GR, Shago M, Zielenska M et al. Primary subcutaneous primitive neuroectodermal tumor with aggressive behavior and an unusual karyotype: case report. Pediatr Dev Pathol 2004; 7: 538–545.
Štítky
Dětská onkologie Chirurgie všeobecná OnkologieČlánek vyšel v časopise
Klinická onkologie
2009 Číslo 2
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Cinitaprid – v Česku nová účinná látka nejen pro léčbu dysmotilitní dyspepsie
- Management pacientů s MPN a neobvyklou kombinací genových přestaveb – systematický přehled a kazuistiky
- Neodolpasse je bezpečný přípravek v krátkodobé léčbě bolesti
- Management péče o pacientku s karcinomem ovaria a neočekávanou mutací CDH1 – kazuistika
Nejčtenější v tomto čísle
- Příprava protinádorové vakcíny pro pacienty s mnohočetným myelomem na bázi dendritických buněk naložených monoklonálním imunoglobulinem
- Trastuzumab v liečbe karcinómu prsníka: mechanizmy účinku a rezistencie
- Klinický význam chromozomálních změn u nádorů kostí a měkkých tkání dětí a mladistvých
- Bevacizumab v kombinaci s kapecitabinem a irinotekanem (XELIRI) v léčbě metastatického kolorektálního karcinomu